Skip to main content

Advertisement

Log in

Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus

Tumor Biology

Abstract

The aim of the study is to explore roles of microRNA (miR)-124a and miR-30d in breast cancer (BC) patients with type 2 diabetes mellitus (T2DM). A total of 144 cases of confirmed diagnosed BC with T2DM, T2DM, BC, or healthy people were enrolled. Among them, BC patients with T2DM were regarded as the experiment group (n = 36), patients with T2DM as the Dm group (n = 36), patients with BC as the Bc group (n = 36), and healthy subjects as the healthy group (n = 36). The fasting insulin resistance index, glycosylated hemoglobin, and estradiol were measured. MiR-124a and miR-30d expressions were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The insulin resistance index was significantly higher in the experiment group compared to the other three groups (all P < 0.05). The glycated hemoglobin was in a normal range in the Bc group and healthy group, but was higher in the experiment group and the Bc group compared to that in the healthy group (both P < 0.05). The serum estradiol level was obviously higher in the Bc group compared with that in the Dm group and the experiment group (both P < 0.05). The expressions of miR-124a and miR-30d were positively correlated with insulin resistance index, BMI and glycosylated hemoglobin (miR-124a r = 0.659, r = 0.785, and r = 0.862; miR-30d r = 0.742, r = 0.805, r = 0.765; all P < 0.001). Insulin resistance index was an independent factor for expressions of miR124-a and miR-30d. MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. Although the mechanism is not clear, miR-124a and miR-30d potentially may be used as therapeutic targets and prognostic markers for BC patients with T2DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Wang RJ, Lu LJ, Jin LB, Li HY, Ren GS, Wu KN, et al. Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of china. Med Oncol. 2014;31(1):788.

    Article  PubMed  Google Scholar 

  2. Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012;131(1):70–82.

    Article  CAS  PubMed  Google Scholar 

  3. Liu X, Hemminki K, Forsti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137(4):903–10.

    Article  CAS  PubMed  Google Scholar 

  4. Luo J, Virnig B, Hendryx M, Wen S, Chelebowski R, Chen C, et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res Treat. 2014;148(1):153–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol. 2012;29(3):1576–80.

    Article  PubMed  Google Scholar 

  6. He DE, Bai JW, Liu J, Du CW, Huang WH, Zhang GJ. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Mol Clin Oncol. 2015;3(3):607–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Li X, Du N, Zhang Q, Li J, Chen X, Liu X, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 2014;5:e1479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853(10):2392–403.

    Article  CAS  PubMed  Google Scholar 

  9. Li J, Li L, Li Z, Gong G, Chen P, Liu H, et al. The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. Gynecol Oncol. 2015;137(1):125–33.

    Article  CAS  PubMed  Google Scholar 

  10. Kim S, Rhee JK, Yoo HJ, Lee HJ, Lee EJ, Lee JW, et al. Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Lett. 2015;357(2):488–97.

    Article  CAS  PubMed  Google Scholar 

  11. Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(3):2248–56.

    Article  PubMed  Google Scholar 

  12. Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 2015;52(3):523–30.

    Article  CAS  PubMed  Google Scholar 

  13. Yu H, Lin X, Wang F, Zhang B, Wang W, Shi H, et al. Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells. Oncol Lett. 2014;7(3):799–804.

    PubMed  Google Scholar 

  14. Zhao X, Mohan R, Ozcan S, Tang X. MicroRNA-30d induces insulin transcription factor mafa and insulin production by targeting mitogen-activated protein 4 kinase 4 (map4k4) in pancreatic beta-cells. J Biol Chem. 2012;287(37):31155–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. PN M. World medical association publishes the revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.

    Google Scholar 

  16. Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, et al. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2015;15:9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord. 2014;19(3):275–83.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Okuno A, Kaji N, Takahashi A, Nagakubo D, Ohno-Ichiki K, Shirai M, et al. Role of insulin resistance in the pathogenesis and development of type 2 diabetes in wbn/kob-lepr(fa) rats. J Vet Med Sci. 2013;75(12):1557–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mizokami-Stout K, Cree-Green M, Nadeau KJ. Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):255–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Liu A, Kushida CA, Reaven GM. Habitual shortened sleep and insulin resistance: an independent relationship in obese individuals. Metabolism. 2013;62(11):1553–6.

    Article  PubMed  Google Scholar 

  21. Yoon SR, Lee JH, Na GY, Seo YJ, Han S, Shin MJ, et al. Glycated hemoglobin is a better predictor than fasting glucose for cardiometabolic risk in non-diabetic Korean women. Clin Nutr Res. 2015;4(2):97–103.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Incani M, Sentinelli F, Perra L, Pani MG, Porcu M, Lenzi A, et al. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: diagnostic impact on obese and lean subjects, and phenotypic characterization. J Diabetes Investig. 2015;6(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  23. Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) study, 1990–2006. Int J Cancer. 2012;131(7):1667–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, et al. Relationship of glycated hemoglobin levels with myocardial injury following elective percutaneous coronary intervention in patients with type 2 diabetes mellitus. PLoS One. 2014;9(7), e101719.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. J Womens Health (Larchmt). 2013;22(12):1043–8.

    Article  Google Scholar 

  26. Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer. 2013;13:503.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Chalasani P, Stopeck A, Clarke K, Livingston R. A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer. Oncologist. 2014;19(11):1127–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M, Trimeche M. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 2014;35(5):4047–56.

    Article  CAS  PubMed  Google Scholar 

  29. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012;3(11):1455–71.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ling HY, Hu B, Hu XB, Zhong J, Feng SD, Qin L, et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3t3-l1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes. 2012;120(9):553–9.

    Article  CAS  PubMed  Google Scholar 

  31. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (bcrp/abcg2) in drug transport—an update. AAPS J. 2015;17(1):65–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The project was supported by the national science and technology project (2013GS500101-05). We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dong-Lin Luo.

Ethics declarations

All patients signed informed consents. The experiment was approved by the ethics committee of our hospital, and the ethical approval for this study conformed to the standards of the Declaration of Helsinki.

Conflicts of interest

None

Additional information

Shu Zhang and Ling-Ji Guo contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, S., Guo, LJ., Zhang, G. et al. Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus. Tumor Biol. 37, 11057–11063 (2016). https://doi.org/10.1007/s13277-016-4981-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4981-6

Keywords

Navigation